Vitrolife AB Reports Strong Q3 Growth, Particularly in the Americas

Vitrolife AB's Q3 2025 Interim Report: Positive Growth in the Americas

On October 23, 2025, Vitrolife AB (publ) released its interim report for the third quarter of 2025, showcasing resilient performance despite challenging currency dynamics. The company reported sales of SEK 835 million, reflecting a 3% increase in local currencies, contrasting with a 4% decline when measured in SEK due to substantial currency volatility.

Regional Performance Overview

Breaking down the sales by region, the Americas demonstrated remarkable strength, recording an impressive growth rate of 11% in local currencies. Conversely, the EMEA region experienced a modest decline of 2%, while the APAC region saw slight growth of 1%. Excluding discontinued operations, EMEA's growth was marginally better at 4%.

Such geographic discrepancies highlight the varying market conditions that the company navigates across its operational territories.

Product Segment Insights

In terms of product performance, Vitrolife's various segments showed differing growth trajectories. Consumables reported a solid increase of 7% in local currencies, while Technologies rose by 8%. However, the Genetics segment remained flat, reflecting a stagnant demand in that particular area. This uneven performance within its product lines suggests opportunities for targeted strategies to bolster lagging areas.

Financial Metrics and Margins

Despite the overall sales dip in SEK, Vitrolife managed to improve its gross margin to 58.9%, up from 58.6% in the previous year. This enhancement can be attributed to a favorable product mix and effective cost management strategies, even amidst a negative currency effect.

The company reported an EBITDA of SEK 253 million with a margin of 30.3%, showcasing its ongoing operational efficiency despite the currency headwinds that have affected overall profitability. The net income totaled SEK 102 million, yielding earnings per share of SEK 0.75, down from SEK 0.85 the previous year.

First Nine Months Performance

For the first nine months of 2025, Vitrolife recorded total sales of SEK 2,548 million, marking a 1% growth in local currencies while declining 4% in SEK. Excluding the impact of discontinued operations, organic growth stood at 4%, indicating a stable underlying performance. Moreover, the company observed an 8% increase in locals sales within the Americas, reinforcing its position in this key market.

Looking Ahead

As Vitrolife navigates through a complex global environment marked by fluctuating currency rates and regional disparities, the solid growth in the Americas offers a promising sign for future performance. The company aims to leverage this momentum while addressing challenges in other regions and product categories. Potential strategies include enhancing product offerings and optimizing supply chains to further improve margins and profitability.

In conclusion, Vitrolife's Q3 2025 performance underscores its resilience and capacity for growth in select markets, with a focus on strategic adjustments to capitalize on emerging opportunities. As the company looks to close the year, stakeholders remain optimistic about its trajectory and commitment to delivering sustainable growth.

For more detailed insights and future updates, please refer to Vitrolife's official investor relations page.